Janssen Reports P-IIIb Study (ESCAPE-TRD) Results of Spravato (esketamine nasal spray) for Treatment-Resistant Major Depressive Disorder
Shots:
- The P-IIIb study evaluating esketamine NS vs quetiapine XR in combination with a continuing selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor across 24 countries in EU, Latin America, Africa & Asia
- The results showed that patients achieved PHQ-9-defined remission (56.8% vs 43.3%) at 8wk. with numbers increasing by 32wk. (68.9% vs 57.2%). The results were consistent with 1EPs analysis & showed a higher remission rate
- Treatment discontinuation due to TEAEs (4.2% vs 11.0%) & showed a favorable tolerability profile, 92.1% vs 12.1% were transient & resolved the same day, 82.6% vs 15.5% reported a TEAE that resolved on the same day. The results were presented at the 36th ECNP 2023
Ref:globnewswire | Image: janssen pharmaceuticals
Related News:- Relmada Therapeutics Reported Results for REL-1017 in the P-III Trial for the Treatment of Major Depressive Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
